Clinical and Pharmacological Implications of Time to Treatment with Interleukin-1 Blockade in ST-Segment Elevation Myocardial Infarction
Copyright © 2023 by The American Society for Pharmacology and Experimental Therapeutics..
Interleukin-1 (IL-1) blockade with anakinra given within 12 hours from reperfusion has been shown to reduce the inflammatory response as well as prevent heart failure (HF) events in patients with STEMI. We sought to determine whether time-to-treatment influences the efficacy of anakinra on systemic inflammation and incidence of HF events in patients with STEMI. We divided the cohort in two groups base6d on the median time from percutaneous coronary intervention (PCI) to investigational drug, and analyzed the effects of anakinra on the area-under-the-curve for C reactive protein (AUC-CRP) and on incidence of the composite endpoint of death or new onset HF. We analyzed data from 139 patients: 84 (60%) treated with anakinra and 55 (40%) with placebo. The median time from PCI to investigational treatment was 271 (182-391) minutes. The AUC-CRP was significantly higher in patients receiving placebo versus anakinra both in those with time from PCI to treatment <271 minutes (222.6 [103.9-325.2] vs. 78.4 [44.3-131.2], P < 0.001) and those with time from PCI to treatment ≥271 minute (235.2 [131.4-603.4] vs. 75.5 [38.9-171.9], P < 0.001) (P > 0.05 for interaction). Anakinra significantly reduced the combined endpoint of death or new onset HF in patients with time from PCI to treatment <271 minutes (5 [11%] vs. 9n[36%], log-rank χ 2 5.985, P = 0.014) as well as in patients with time from PCI to drug ≥271 minutes (2n[5%] vs. 7 [23%], log-rank χ 2 3.995, P = 0.046) (P > 0.05 for interaction). IL-1 blockade with anakinra blunts the acute systemic inflammatory response and prevents HF events independent of time-to-treatment. SIGNIFICANCE STATEMENT: In patients with ST segment elevation presenting within 12 hours of pain onset and treated within 12 hours of reperfusion, interleukin-1 blockade with anakinra blunts the acute systemic inflammatory response, a surrogate of interleukin-1 activity, and prevents heart failure events independent of time-to-treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:386 |
|---|---|
| Enthalten in: |
The Journal of pharmacology and experimental therapeutics - 386(2023), 2 vom: 10. Aug., Seite 156-163 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Del Buono, Marco Giuseppe [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9007-41-4 |
|---|
| Anmerkungen: |
Date Completed 19.07.2023 Date Revised 02.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1124/jpet.123.001601 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355421755 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355421755 | ||
| 003 | DE-627 | ||
| 005 | 20231226064318.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1124/jpet.123.001601 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355421755 | ||
| 035 | |a (NLM)37037651 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Del Buono, Marco Giuseppe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical and Pharmacological Implications of Time to Treatment with Interleukin-1 Blockade in ST-Segment Elevation Myocardial Infarction |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.07.2023 | ||
| 500 | |a Date Revised 02.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 by The American Society for Pharmacology and Experimental Therapeutics. | ||
| 520 | |a Interleukin-1 (IL-1) blockade with anakinra given within 12 hours from reperfusion has been shown to reduce the inflammatory response as well as prevent heart failure (HF) events in patients with STEMI. We sought to determine whether time-to-treatment influences the efficacy of anakinra on systemic inflammation and incidence of HF events in patients with STEMI. We divided the cohort in two groups base6d on the median time from percutaneous coronary intervention (PCI) to investigational drug, and analyzed the effects of anakinra on the area-under-the-curve for C reactive protein (AUC-CRP) and on incidence of the composite endpoint of death or new onset HF. We analyzed data from 139 patients: 84 (60%) treated with anakinra and 55 (40%) with placebo. The median time from PCI to investigational treatment was 271 (182-391) minutes. The AUC-CRP was significantly higher in patients receiving placebo versus anakinra both in those with time from PCI to treatment <271 minutes (222.6 [103.9-325.2] vs. 78.4 [44.3-131.2], P < 0.001) and those with time from PCI to treatment ≥271 minute (235.2 [131.4-603.4] vs. 75.5 [38.9-171.9], P < 0.001) (P > 0.05 for interaction). Anakinra significantly reduced the combined endpoint of death or new onset HF in patients with time from PCI to treatment <271 minutes (5 [11%] vs. 9n[36%], log-rank χ 2 5.985, P = 0.014) as well as in patients with time from PCI to drug ≥271 minutes (2n[5%] vs. 7 [23%], log-rank χ 2 3.995, P = 0.046) (P > 0.05 for interaction). IL-1 blockade with anakinra blunts the acute systemic inflammatory response and prevents HF events independent of time-to-treatment. SIGNIFICANCE STATEMENT: In patients with ST segment elevation presenting within 12 hours of pain onset and treated within 12 hours of reperfusion, interleukin-1 blockade with anakinra blunts the acute systemic inflammatory response, a surrogate of interleukin-1 activity, and prevents heart failure events independent of time-to-treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 650 | 7 | |a Interleukin 1 Receptor Antagonist Protein |2 NLM | |
| 650 | 7 | |a Interleukin-1 |2 NLM | |
| 700 | 1 | |a Damonte, Juan Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Moroni, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Chiabrando, Juan Guido |e verfasserin |4 aut | |
| 700 | 1 | |a Markley, Roshanak |e verfasserin |4 aut | |
| 700 | 1 | |a Turlington, Jeremy |e verfasserin |4 aut | |
| 700 | 1 | |a Trankle, Cory R |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Le |e verfasserin |4 aut | |
| 700 | 1 | |a Biondi-Zoccai, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Kontos, Michael C |e verfasserin |4 aut | |
| 700 | 1 | |a Roberts, Charlotte S |e verfasserin |4 aut | |
| 700 | 1 | |a Van Tassell, Benjamin W |e verfasserin |4 aut | |
| 700 | 1 | |a Abbate, Antonio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of pharmacology and experimental therapeutics |d 1945 |g 386(2023), 2 vom: 10. Aug., Seite 156-163 |w (DE-627)NLM000006475 |x 1521-0103 |7 nnns |
| 773 | 1 | 8 | |g volume:386 |g year:2023 |g number:2 |g day:10 |g month:08 |g pages:156-163 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1124/jpet.123.001601 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 386 |j 2023 |e 2 |b 10 |c 08 |h 156-163 | ||